best peptides for leaky gut FAQ

Structural tight junction damage doesn't respond to microbial rebalancing alone. You're treating downstream inflammation without addressing the broken barrier. BPC-157 directly repairs occludin and claudin proteins that dietary interventions cannot restore. Combine peptide therapy with elimination protocols for 4–6 weeks, then reintroduce foods systematically while monitoring symptom recurrence. The peptide addresses the damage; the diet reduces ongoing insult.

Subcutaneous BPC-157 occasionally causes mild nausea in the first 3–5 days as mucosal healing accelerates and detoxification pathways activate. This is distinct from worsening gut symptoms. If diarrhea or cramping increases, the issue is likely contamination or improper reconstitution. Switch to oral administration in enteric capsules, which bypasses systemic circulation initially and concentrates the peptide at the intestinal lining. Nausea that persists beyond one week warrants stopping and consulting a prescriber.

KPV requires direct mucosal contact. If you're using immediate-release capsules, they dissolve in the stomach and degrade before reaching the colon. Switch to delayed-release or enteric-coated formulations designed to release in the distal small intestine and colon. Dosing also matters: studies showing efficacy used 1–2 mg daily, not 500 mcg. Fecal calprotectin and C-reactive protein are the markers that track. Retest at 4–6 weeks, not sooner.

Continue the peptide protocol but expect incomplete barrier restoration. BPC-157 repairs tight junction damage through VEGF signaling, but ongoing exposure to gluten (in celiac patients), alcohol, or NSAIDs creates new epithelial injury faster than peptide-mediated repair occurs. A 2019 study in Digestive Diseases and Sciences found continued alcohol consumption prevented intestinal barrier healing despite proton pump inhibitor therapy. The same principle applies to peptides. Remove the inciting agent first, then peptide protocols accelerate repair that diet alone achieves slowly.

BPC-157 demonstrates oral bioavailability in gastric environments, though small intestine targeting requires higher doses. Research suggests 3–5× the subcutaneous dose orally to achieve equivalent mucosal effects. KPV's tripeptide structure allows liposomal or nanoparticle encapsulation for oral delivery, though commercial formulations meeting pharmaceutical purity standards remain limited. Thymosin Alpha-1 lacks oral bioavailability entirely due to rapid enzymatic degradation. For injection-averse patients, BPC-157 oral + dietary intervention represents the most evidence-backed non-injection approach, accepting longer timelines for barrier restoration.

Temporary symptom exacerbation during NF-κB inhibition can occur as bacterial endotoxin clearance increases. When KPV reduces intestinal inflammation, previously sequestered LPS (lipopolysaccharide) in inflamed tissue gets mobilised into lymphatic circulation before liver clearance. Creating transient endotoxemia symptoms (fatigue, brain fog, low-grade fever). This typically resolves within 5–7 days as hepatic detoxification catches up. If symptoms persist beyond two weeks or worsen progressively, discontinue and evaluate for underlying infection or SIBO that KPV's anti-inflammatory effects may be masking.